P
Paul F. Pollack
Researcher at Janssen Pharmaceutica
Publications - 52
Citations - 3902
Paul F. Pollack is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Adalimumab & Charm (quantum number). The author has an hindex of 18, co-authored 52 publications receiving 3668 citations. Previous affiliations of Paul F. Pollack include Abbott Laboratories.
Papers
More filters
Journal ArticleDOI
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
William J. Sandborn,Stephen B. Hanauer,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,J. D. Kent,Barry Bittle,Ju Li,Paul F. Pollack +11 more
TL;DR: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn’s disease naive to anti-TNF treatment in a follow-on randomised controlled trial.
Journal ArticleDOI
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Jean-Frederic Colombel,Remo Panaccione,Geert R. D'Haens,Ju Li,Marie R. Rosenfeld,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab as discussed by the authors.
Journal Article
Adalimumab for maintenance treatment of Crohn's disease : results of the CLASSIC II trial. Commentary
Julián Panés,Subrata Ghosh,W J Sandborn,S. B. Hanauer,Paul Rutgeerts,R Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Doug Wolf,J. D. Kent,B. Bittle,Ji Li,Paul F. Pollack +13 more
TL;DR: Adalimumab was generally well-tolerated in all patients and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn's disease naive to anti-TNF treatment as mentioned in this paper.
CLINICAL—ALIMENTARY TRACT Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts,Gert A. Van Assche,William J. Sandborn,Douglas C. Wolf,Karel Geboes,W. Reinisch,Ashok Kumar,Andreas Lazar,Anne Camez,Kathleen Lomax,Paul F. Pollack +10 more
Journal ArticleDOI
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial
Edward V. Loftus,Brian G. Feagan,Jean-Frederic Colombel,David T. Rubin,Eric Q. Wu,Andrew P. Yu,Paul F. Pollack,Jingdong Chao,Parvez Mulani +8 more
TL;DR: Adalimumab maintenance therapy provided sustained improvements in HRQOL for patients with moderate to severe Crohn's disease through week 56, compared with patients who were assigned to placebo after induction therapy.